NCT04351100 is a clinical trial of Diacerein in Ocular Surface Disease, sponsored by Chulalongkorn University.

Who is sponsoring NCT04351100?

NCT04351100 is sponsored by Chulalongkorn University.

What drugs are being tested in NCT04351100?

Interventions in NCT04351100: Diacerein.

What condition does NCT04351100 study?

NCT04351100 studies Ocular Surface Disease, Osteoarthritis, Diacerein.

Is NCT04351100 still recruiting?

NCT04351100 is currently completed. Last updated 10 August 2021.

Last reviewed 2021-08-10 · How we verify

NCT04351100

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Diacerein on Ocular Surface Disease in Degenerative Arthritis Patients

Completed Last updated 10 August 2021

What this trial tests

trial testing Diacerein in Ocular Surface Disease in 34 participants. Completed in 31 July 2020.

Timeline

1 October 2019

Primary endpoint
31 July 2020

31 July 2020

Quick facts

Lead sponsor	Chulalongkorn University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	34
Start date	1 October 2019
Primary completion	31 July 2020
Estimated completion	31 July 2020
Sites	1 location across Thailand

Drugs / interventions tested

Diacerein (DIACEREIN) — full drug profile →

Conditions studied

Ocular Surface Disease — all drugs for Ocular Surface Disease →
Osteoarthritis — all drugs for Osteoarthritis →
Diacerein — all drugs for Diacerein →

Sponsor

Chulalongkorn University

Who can join

18 and older, any sex, with Ocular Surface Disease or Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Dry eyes is multi-factorial disease which inflammation play etiological role. Diacerein is drug which has anti-inflammatory effect by antagonist Interleukin-1, decrease Interleukin-1 receptor, increase Interleukin-1 Receptor antagonist. This observational study enrolled participants who going to take diacerein for osteoarthritis, measure corneal staining score, Ocular surface disease index score, Tear Osmolarity, Tear break up time, Schirmer 1 test, Interleukin-1 Receptor antagonist, Interleukin-1 alpha, Interleukin-1 beta level in tear at the time of enrollment and after 2 months.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Efficacy of Interleukin-1β Inhibitor on Dry Eye Disease in Patients with Degenerative Arthritis.
Treewipanon N, Kasetsuwan N, Reinprayoon U, Satitpitakul V, et al · · 2023 · cited 7× · PMID 37841899 · DOI 10.2147/opth.s419310
Advances in Drug Delivery Science for Diacerein: Strategies to Enhance Solubility, Bioavailability, and Pharmacokinetic Performance.
Naseri M, Ghobakhlou S, Heidarizade N, Akbari ME, et al · · 2025 · PMID 41471053 · DOI 10.3390/pharmaceutics17121539

Verify or expand the search:

Other trials of Diacerein

Trials testing the same drug.

NCT07352306 — Topical Diacerein in Psoriasis Vulgaris · Phase 4 · not yet recruiting
NCT05226754 — Study Design of the Diacerein in Patients With Covid-19 · Phase 2 · unknown
NCT03404479 — Trial to Evaluate Efficacy and Safety of Combination of Diacerein and Celecoxib Administered in Patients With Knee OA · Phase 4 · unknown
NCT02242149 — Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects · Phase 3 · completed

Other recruiting trials for Ocular Surface Disease

Currently open trials in the same condition.

NCT07537426 — The Efficacy of Intradermal Acupuncture for Ocular Surface Diseases After Intractable Facial Paralysis · NA · recruiting
NCT07502378 — Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic · Phase 4 · recruiting
NCT07297849 — Eyelid Closure in Keratometry · NA · recruiting
NCT06555367 — Clinical Application Research of Scleral Lenses in Ocular Surface Diseases · recruiting
NCT06355128 — A Cross-sectional Study of Ocular Manifestations During the Covid-19 Pandemic in Hubei Province · active not recruiting

Other Chulalongkorn University trials

Trials by the same sponsor.

NCT07458659 — Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myel · EARLY_PHASE1 · not yet recruiting
NCT07346118 — Fluid Balance Guided by Modified Venous Excess Ultrasonography Versus Standard Care in Patients With Acute Kidney Injury · NA · not yet recruiting
NCT07388862 — Comparison of Treatment Outcome of Pulpotomy With Versus Without Dental Operating Microscope in Carious Mature Permanent · EARLY_PHASE1 · not yet recruiting
NCT07373977 — Comparison of Postoperative Pain After Pulpotomy Performed With Versus Without Dental Operating Microscope in Carious Ma · EARLY_PHASE1 · not yet recruiting
NCT07078929 — Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04351100 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chulalongkorn University
Last refreshed: 10 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04351100.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing